Switch to:
Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Accounts Payable & Accrued Expense
$3,855 Mil (As of Jun. 2016)

Teva Pharmaceutical Industries Ltd's quarterly accounts payable & accrued expense declined from Dec. 2015 ($3,594 Mil) to Mar. 2016 ($3,528 Mil) but then increased from Mar. 2016 ($3,528 Mil) to Jun. 2016 ($3,855 Mil).

Teva Pharmaceutical Industries Ltd's annual accounts payable & accrued expense declined from Dec. 2013 ($3,317 Mil) to Dec. 2014 ($3,171 Mil) but then increased from Dec. 2014 ($3,171 Mil) to Dec. 2015 ($3,594 Mil).


Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Teva Pharmaceutical Industries Ltd Annual Data

Accounts Payable & Accrued Expense 3,3291,3832,2442,3492,5253,5723,3763,3173,1713,594

Teva Pharmaceutical Industries Ltd Quarterly Data

Accounts Payable & Accrued Expense 3,1433,0262,8943,1713,0362,9762,9643,5943,5283,855
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)